Redeye returns with a more in-depth take on the Q3 report. The miss on sales and EBIT increased the market’s scepticism, but we believe the coming quarters will reinforce the market’s understanding of BONESUPPORT’s profitable, high-growth sales trajectory.
LÄS MER
